699 related articles for article (PubMed ID: 20064608)
1. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies.
Zhang YF; Wang JC; Bian DY; Zhang X; Zhang Q
Eur J Pharm Biopharm; 2010 Mar; 74(3):467-73. PubMed ID: 20064608
[TBL] [Abstract][Full Text] [Related]
2. Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo.
Xiong XB; Huang Y; Lu WL; Zhang H; Zhang X; Zhang Q
Pharm Res; 2005 Jun; 22(6):933-9. PubMed ID: 15948037
[TBL] [Abstract][Full Text] [Related]
3. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Pharm Sci; 2005 Aug; 94(8):1782-93. PubMed ID: 15986461
[TBL] [Abstract][Full Text] [Related]
4. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic.
Xiong XB; Huang Y; Lu WL; Zhang X; Zhang H; Nagai T; Zhang Q
J Control Release; 2005 Oct; 107(2):262-75. PubMed ID: 16125816
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive study of iRGD-modified liposomes with improved chemotherapeutic efficacy on B16 melanoma.
Dai W; Fan Y; Zhang H; Wang X; Zhang Q; Wang X
Drug Deliv; 2015 Jan; 22(1):10-20. PubMed ID: 24735248
[TBL] [Abstract][Full Text] [Related]
6. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide.
Chen X; Wang X; Wang Y; Yang L; Hu J; Xiao W; Fu A; Cai L; Li X; Ye X; Liu Y; Wu W; Shao X; Mao Y; Wei Y; Chen L
J Control Release; 2010 Jul; 145(1):17-25. PubMed ID: 20307599
[TBL] [Abstract][Full Text] [Related]
7. Sequential treatment of drug-resistant tumors with RGD-modified liposomes containing siRNA or doxorubicin.
Jiang J; Yang SJ; Wang JC; Yang LJ; Xu ZZ; Yang T; Liu XY; Zhang Q
Eur J Pharm Biopharm; 2010 Oct; 76(2):170-8. PubMed ID: 20600887
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
[TBL] [Abstract][Full Text] [Related]
9. Enhanced Specificity and Drug Delivery in Tumors by cRGD-Anchoring Thermosensitive Liposomes.
Dicheva BM; ten Hagen TL; Seynhaeve AL; Amin M; Eggermont AM; Koning GA
Pharm Res; 2015 Dec; 32(12):3862-76. PubMed ID: 26202516
[TBL] [Abstract][Full Text] [Related]
10. Increasing the antitumor efficacy of doxorubicin-loaded liposomes with peptides anchored via a chelator lipid.
Herringson TP; Altin JG
J Drug Target; 2011 Sep; 19(8):681-9. PubMed ID: 21142652
[TBL] [Abstract][Full Text] [Related]
11. Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent.
Sochanik A; Mitrus I; Smolarczyk R; Cichoń T; Snietura M; Czaja M; Szala S
Arch Immunol Ther Exp (Warsz); 2010 Jun; 58(3):235-45. PubMed ID: 20383751
[TBL] [Abstract][Full Text] [Related]
12. [Preparation of doxorubicin-loaded stealth liposomes modified with RGD mimetic and cellular association in vitro].
Xiong XB; Huang Y; Lü WL; Zhang X; Zhang H; Zhang Q
Yao Xue Xue Bao; 2005 Dec; 40(12):1085-90. PubMed ID: 16496670
[TBL] [Abstract][Full Text] [Related]
13. [Cellular toxicity and anti-tumor efficacy of iRGD modified doxorubixin loaded sterically stabilized liposomes].
Zhao B; Fan YC; Wang XQ; Dai WB; Zhang Q; Wang XL
Yao Xue Xue Bao; 2013 Mar; 48(3):417-22. PubMed ID: 23724658
[TBL] [Abstract][Full Text] [Related]
14. The antitumor activity of a doxorubicin loaded, iRGD-modified sterically-stabilized liposome on B16-F10 melanoma cells: in vitro and in vivo evaluation.
Yu KF; Zhang WQ; Luo LM; Song P; Li D; Du R; Ren W; Huang D; Lu WL; Zhang X; Zhang Q
Int J Nanomedicine; 2013; 8():2473-85. PubMed ID: 23885174
[TBL] [Abstract][Full Text] [Related]
15. Combination drug delivery via multilamellar vesicles enables targeting of tumor cells and tumor vasculature.
Liu Y; Kim YJ; Siriwon N; Rohrs JA; Yu Z; Wanga P
Biotechnol Bioeng; 2018 Jun; 115(6):1403-1415. PubMed ID: 29457630
[TBL] [Abstract][Full Text] [Related]
16. A tumor vasculature targeted liposome delivery system for combretastatin A4: design, characterization, and in vitro evaluation.
Nallamothu R; Wood GC; Pattillo CB; Scott RC; Kiani MF; Moore BM; Thoma LA
AAPS PharmSciTech; 2006 Apr; 7(2):E32. PubMed ID: 16796350
[TBL] [Abstract][Full Text] [Related]
17. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes.
Xiang Y; Liang L; Wang X; Wang J; Zhang X; Zhang Q
J Control Release; 2011 Jun; 152(3):402-10. PubMed ID: 21435361
[TBL] [Abstract][Full Text] [Related]
18. Mild hyperthermia triggered doxorubicin release from optimized stealth thermosensitive liposomes improves intratumoral drug delivery and efficacy.
Li L; ten Hagen TL; Hossann M; Süss R; van Rhoon GC; Eggermont AM; Haemmerich D; Koning GA
J Control Release; 2013 Jun; 168(2):142-50. PubMed ID: 23524188
[TBL] [Abstract][Full Text] [Related]
19. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas.
Chen H; Qin Y; Zhang Q; Jiang W; Tang L; Liu J; He Q
Eur J Pharm Sci; 2011 Sep; 44(1-2):164-73. PubMed ID: 21782939
[TBL] [Abstract][Full Text] [Related]
20. RGD-modified pH-sensitive liposomes for docetaxel tumor targeting.
Chang M; Lu S; Zhang F; Zuo T; Guan Y; Wei T; Shao W; Lin G
Colloids Surf B Biointerfaces; 2015 May; 129():175-82. PubMed ID: 25851582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
